Astria Therapeutics (ATXS) announced final results from the target enrollment group of 16 patients in the ALPHA-STAR Phase 1b/2 clinical trial ...

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced positive final results from ...

CRISPR gene editing based treatment reduced HAE attacks rates by up to 80%. NTLA-2002 was well tolerated by patients. The ...

In a phase 1 trial, Sebetralstat was shown to be able to suppress plasma kallikrein activity nearly completely. A single 600 mg dose of Sebetralstat produced a 98% inhibition of plasma kallikrein ...

One capsule of Orladeyo per day works to prevent HAE attacks by decreasing the activity of plasma kallikrein. Orladeyo (berotralstat) is a plasma kallikrein inhibitor indicated for prophylaxis to ...

I broadly divided this into three classes: “plasma kallikrein inhibitors, bradykinin B2 receptor antagonists, and C1 Esterase Inhibitors, and two types — preventive treatments which are ...